GW4869 Can Inhibit Epithelial-Mesenchymal Transition and Extracellular HSP90α in Gefitinib-Sensitive NSCLC Cells
OncoTargets and Therapy · 2023-11 · Volume 16 · 913-922
DOI: 10.2147/ott.s428707 ↗Kurz gefasst
Fachartikel in der Zeitschrift OncoTargets and Therapy, 2023-11. Verfasst von Xuan Wan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, …. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Objective
GW4869 is an exosomal inhibitor. It is necessary to delay the occurrence of gefitinib resistance during non-small-cell lung cancer (NSCLC) treatment. This study aimed to investigate the anti-tumor effects of GW4869 on epithelial-mesenchymal transition (EMT) and expression of extracellular heat shock protein 90α (eHSP90α) that contributes to acquired resisitance. Our study provides a new sight into the treatment of EGFR-mutated NSCLC. Materials and Methods: We performed western blotting to detect levels of EMT and eHSP90α. Wound healing and transwell assays were performed to evaluate the behavioral dynamics of EMT. A nude mouse model of HCC827 was established in vivo.
Results
GW4869 inhibited the expression of eHSP90α, EMT, invasion and migration abilities of HCC827 and PC9. GW4869 enhanced sensitivity to gefitinib in BALB/c nude mice bearing tumors of HCC827.
Conclusion
These studies suggest that GW4869 can inhibit EMT and extracellular HSP90α, providing new strategies for enhancing gefitinib sensitivity in NSCLC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510515, People's Republic of China.
- BSL-3 Laboratory, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, Guangdong Province, 510515, People's Republic of China.
Zitieren
APA
Wan, X., Fang, Y., Du, J., Cai, S., & Dong, H. (2023). GW4869 Can Inhibit Epithelial-Mesenchymal Transition and Extracellular HSP90α in Gefitinib-Sensitive NSCLC Cells. OncoTargets and Therapy, Volume 16, 913-922. https://doi.org/10.2147/ott.s428707
Vancouver
Wan X, Fang Y, Du J, Cai S, Dong H. GW4869 Can Inhibit Epithelial-Mesenchymal Transition and Extracellular HSP90α in Gefitinib-Sensitive NSCLC Cells. OncoTargets and Therapy. 2023;Volume 16:913-922. doi:10.2147/ott.s428707
BibTeX
@article{Wan2023,
author = {Wan, Xuan and Fang, Yuting and Du, Jiangzhou and Cai, Shaoxi and Dong, Hangming},
title = {GW4869 Can Inhibit Epithelial-Mesenchymal Transition and Extracellular HSP90α in Gefitinib-Sensitive NSCLC Cells},
journal = {OncoTargets and Therapy},
year = {2023},
volume = {Volume 16},
pages = {913--922},
doi = {10.2147/ott.s428707}
}
EUVIMED